Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Epitiostanol

From Wikipedia, the free encyclopedia
Chemical compound

Pharmaceutical compound
Epitiostanol
Clinical data
Trade namesThiodrol
Other namesEpithiostanol; Epithioandrostanol; 10275-S; 2α,3α-Epithio-5α-androstan-17β-ol; 2α,3α-Epithio-4,5α-dihydrotestosterone; 2α,3α-Epithio-DHT
Routes of
administration
Intramuscular injection
Drug classAndrogen;Anabolic steroid;Antiestrogen
Identifiers
  • (1S,3AS,3bR,5aS,6aS,7aR,8aS,8bS,10aS)-8a,10a-dimethylhexadecahydro-1H-cyclopenta[7,8]phenanthro[2,3-b]thiiren-1-ol
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC19H30OS
Molar mass306.51 g·mol−1
3D model (JSmol)
  • CC12CCC3C(C1CCC2O)CCC4C3(CC5C(C4)S5)C
  • InChI=InChI=1S/C19H30OS/c1-18-8-7-14-12(13(18)5-6-17(18)20)4-3-11-9-15-16(21-15)10-19(11,14)2/h11-17,20H,3-10H2,1-2H3
  • Key:OBMLHUPNRURLOK-UHFFFAOYSA-N

Epitiostanol, sold under the brand nameThiodrol, is aninjectedantiestrogen andanabolic–androgenic steroid (AAS) of thedihydrotestosterone (DHT) group which was described in the literature in 1965 and has been marketed inJapan as anantineoplastic agent for the treatment ofbreast cancer since 1977.[1][2][3][4][5]

Medical uses

[edit]

Epitiostanol is used as an antiestrogen and antineoplastic agent in the treatment of breast cancer.[1][2][3][4][5] It has also been found to be effective in the treatment ofgynecomastia.[6][7]

Side effects

[edit]
See also:Anabolic steroid § Adverse effects

Aprodrug of epitiostanol,mepitiostane, which is also marketed for the treatment of breast cancer, is reported to show a high rate ofvirilizingside effects such asacne,hirsutism, andvoice changes in women.[8]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Epitiostanol binds directly to theandrogen receptor (AR) andestrogen receptor (ER), where it acts as anagonist andantagonist, respectively.[3][5][9][10] It is described aspotent in its activity as an antiestrogen and comparatively weak as an AAS.[7] In any case, in terms of AASpotency, epitiostanol has been found to have 11 times theanabolic activity and approximately equalandrogenic activity relative to that of the reference AASmethyltestosterone.[11] Themechanism of action of epitiostanol in breast cancer is multimodal; it directly suppresses tumor growth through activation of the AR and inhibition of the ER, and, inpremenopausal women, it additionally acts as anantigonadotropin and reducing systemicestrogen levels via AR activation and consequent suppression of thehypothalamic-pituitary-gonadal axis.[5][12] Epitiostanol is unique among AAS in acting as an antagonist of the ER.[citation needed]

Pharmacokinetics

[edit]

Similarly to the case oftestosterone, epitiostanol shows poorbioavailability and weak therapeutic efficacy when takenorally due to extensivefirst-pass metabolism.[13] As such, it must instead be administered viaintramuscular injection.[13]

Chemistry

[edit]
See also:List of androgens/anabolic steroids

Epitiostanol, also known as 2α,3α-epithio-4,5α-dihydrotestosterone (2α,3α-epithio-DHT) or as 2α,3α-epithio-5α-androstan-17β-ol, is asyntheticandrostanesteroid and aderivative of DHT.[1][2]Mepitiostane, a derivative of epitiostanol with a C17αmethoxycyclopentaneether substitution, is anorally activeprodrug of epitiostanol.[14][15] Another derivative,methylepitiostanol (2α,3α-epithio-17α-methyl-5α-androstan-17β-ol), has amethyl group at the C17α position and is similarly an orally active variant of epitiostanol; it has surfaced as a noveldesigner steroid.[12]

Society and culture

[edit]

Generic names

[edit]

Epitiostanol is thegeneric name of the drug and itsINNTooltip International Nonproprietary Name andJANTooltip Japanese Accepted Name.[1][2]

References

[edit]
  1. ^abcdElks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 492–.ISBN 978-1-4757-2085-3.
  2. ^abcdIndex Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 394–.ISBN 978-3-88763-075-1.
  3. ^abcTimmerman H (20 November 1995).QSAR and Drug Design: New Developments and Applications. Elsevier. pp. 125, 145.ISBN 978-0-08-054500-4.
  4. ^abWilliam Andrew Publishing (22 October 2013).Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1455–.ISBN 978-0-8155-1856-3.
  5. ^abcdMatsuzawa A, Yamamoto T (December 1977). "Antitumor effect of two oral steroids, mepitiostane and fluoxymesterone, on a pregnancy-dependent mouse mammary tumor (TPDMT-4)".Cancer Research.37 (12):4408–4415.PMID 922732.
  6. ^Kurachi K, Aono T, Tomoyama J, Matsumoto K, Nakasima A (January 1975). "Effects of 2alpha, 3alpha-epithio-5alpha-androstan-17beta-ol (epitiostanol) on hypothalamo-pituitary-gonadal axis in humans".Acta Obstetrica et Gynaecologica Japonica.22 (1). Japanese Obstetrical and Gynecological Society:42–8.PMID 1224948.
  7. ^abAbe O, Kumaoka S, Yamamoto H (December 1973). "2α 3α-Epithio-5α-androstan-17β-ol in Treatment of Gynecomastia".Japanese Journal of Clinical Oncology.3 (2):99–104.doi:10.1093/oxfordjournals.jjco.a039832.ISSN 1465-3621.
  8. ^Inoue K, Okazaki K, Morimoto T, Hayashi M, Uyama S, Sonoo H, et al. (May 1978). "Therapeutic value of mepitiostane in the treatment of advanced breast cancer".Cancer Treatment Reports.62 (5):743–745.PMID 657160.
  9. ^Matsuzawa A (27 June 1986)."Hormone Dependence and Independence in Mammary Tumors in Mice". In Bourne GH, Heon KW, Friedlander M (eds.).International Review of Cytology. Vol. 103. Academic Press. pp. 319–.ISBN 978-0-08-058640-3.
  10. ^Croll RP, Wang C (2007). "Possible roles of sex steroids in the control of reproduction in bivalve molluscs".Aquaculture.272 (1–4):76–86.Bibcode:2007Aquac.272...76C.doi:10.1016/j.aquaculture.2007.06.031.ISSN 0044-8486.
  11. ^Brueggemeier RW (2006). "Sex Hormones (Male): Analogs and Antagonists".Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH Verlag GmbH & Co. KGaA.doi:10.1002/3527600906.mcb.200500066.ISBN 3-527-60090-6.
  12. ^abRahnema CD, Crosnoe LE, Kim ED (March 2015)."Designer steroids - over-the-counter supplements and their androgenic component: review of an increasing problem".Andrology.3 (2):150–155.doi:10.1111/andr.307.PMID 25684733.S2CID 6999218.
  13. ^abIchihashi T, Kinoshita H, Yamada H (July 1991). "Absorption and disposition of epithiosteroids in rats (2): Avoidance of first-pass metabolism of mepitiostane by lymphatic absorption".Xenobiotica; the Fate of Foreign Compounds in Biological Systems.21 (7):873–880.doi:10.3109/00498259109039527.PMID 1776263.
  14. ^Ichihashi T, Kinoshita H, Takagishi Y, Yamada H (October 1991). "Intrinsic lymphatic partition rate of mepitiostane, epitiostanol, and oleic acid absorbed from rat intestine".Pharmaceutical Research.8 (10):1302–1306.doi:10.1023/A:1015864131681.PMID 1796049.S2CID 31203405.
  15. ^Ichihashi T, Takagishi Y, Yamada H (December 1992). "Factors determining the intrinsic lymphatic partition rate of epitiostanol and mepitiostane".Pharmaceutical Research.9 (12):1617–1621.doi:10.1023/A:1015824710957.PMID 1488406.S2CID 2881279.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
Androgens
(incl.AASTooltip anabolic–androgenic steroid)
ARTooltip Androgen receptoragonists
Progonadotropins
Antiandrogens
ARTooltip Androgen receptorantagonists
Steroidogenesis
inhibitors
5α-Reductase
Others
Antigonadotropins
Others
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Epitiostanol&oldid=1303035511"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp